Baseline characteristics of patients enrolled on TT3A (protocol UARK2003-33) and TT3B (protocol UARK2006-66)
| Variable . | TT3A (2003-33) . | TT3B (2006-66) . | P* . |
|---|---|---|---|
| Age ≥ 65 y | 36/142 (25) | 35/128 (27) | .711 |
| Albumin level < 3.5 g/dL | 31/142 (22) | 58/127 (46) | < .001 |
| B2M level ≥ 3.5 mg/L | 63/142 (44) | 70/125 (56) | .058 |
| ISS Stage I | 66/142 (46) | 37/125 (30) | .005 |
| ISS Stage II | 43/142 (30) | 53/125 (42) | .039 |
| ISS Stage III | 33/142 (23) | 35/125 (28) | .373 |
| Creatinine level ≥ 2.0 mg/dL | 13/142 (9) | 9/127 (7) | .537 |
| CRP level ≥ 8 mg/L | 54/142 (38) | 44/127 (35) | .565 |
| Hb level < 10 g/dL | 40/142 (28) | 39/127 (31) | .648 |
| LDH level ≥ 190 U/L | 38/142 (27) | 32/127 (25) | .770 |
| Cytogenetic abnormalities | 55/141 (39) | 49/128 (39) | .984 |
| Baseline 70-gene high risk | 22/142 (15) | 27/128 (21) | .233 |
| GEP CD-1 subgroup | 3/142 (2) | 13/128 (10) | .005 |
| GEP CD-2 subgroup | 11/142 (8) | 21/128 (16) | .028 |
| GEP HY subgroup | 40/142 (28) | 34/128 (27) | .768 |
| GEP LB subgroup | 18/142 (13) | 10/128 (8) | .191 |
| GEP MF subgroup | 10/142 (7) | 8/128 (6) | .794 |
| GEP MS subgroup | 13/142 (9) | 20/128 (16) | .105 |
| GEP PR subgroup | 15/142 (11) | 19/128 (15) | .290 |
| GEP Proliferation Index ≥ 10 | 20/142 (14) | 14/128 (11) | .436 |
| GEP TP53 deletion | 17/142 (12) | 12/128 (9) | .491 |
| Variable . | TT3A (2003-33) . | TT3B (2006-66) . | P* . |
|---|---|---|---|
| Age ≥ 65 y | 36/142 (25) | 35/128 (27) | .711 |
| Albumin level < 3.5 g/dL | 31/142 (22) | 58/127 (46) | < .001 |
| B2M level ≥ 3.5 mg/L | 63/142 (44) | 70/125 (56) | .058 |
| ISS Stage I | 66/142 (46) | 37/125 (30) | .005 |
| ISS Stage II | 43/142 (30) | 53/125 (42) | .039 |
| ISS Stage III | 33/142 (23) | 35/125 (28) | .373 |
| Creatinine level ≥ 2.0 mg/dL | 13/142 (9) | 9/127 (7) | .537 |
| CRP level ≥ 8 mg/L | 54/142 (38) | 44/127 (35) | .565 |
| Hb level < 10 g/dL | 40/142 (28) | 39/127 (31) | .648 |
| LDH level ≥ 190 U/L | 38/142 (27) | 32/127 (25) | .770 |
| Cytogenetic abnormalities | 55/141 (39) | 49/128 (39) | .984 |
| Baseline 70-gene high risk | 22/142 (15) | 27/128 (21) | .233 |
| GEP CD-1 subgroup | 3/142 (2) | 13/128 (10) | .005 |
| GEP CD-2 subgroup | 11/142 (8) | 21/128 (16) | .028 |
| GEP HY subgroup | 40/142 (28) | 34/128 (27) | .768 |
| GEP LB subgroup | 18/142 (13) | 10/128 (8) | .191 |
| GEP MF subgroup | 10/142 (7) | 8/128 (6) | .794 |
| GEP MS subgroup | 13/142 (9) | 20/128 (16) | .105 |
| GEP PR subgroup | 15/142 (11) | 19/128 (15) | .290 |
| GEP Proliferation Index ≥ 10 | 20/142 (14) | 14/128 (11) | .436 |
| GEP TP53 deletion | 17/142 (12) | 12/128 (9) | .491 |
Values are expressed as number with Factor/number with valid data for factor (%).
ISS indicates International Staging System; and Hb, hemoglobin.
Determined with chi-square test.